Skip to main content

DC Partnership for HIV/AIDS Progress (DC PFAP)

In 2008, the National Institutes of Health and the DC Department of Health collaborated to establish the DC Partnership for HIV/AIDS Progress (DC PFAP), a partnership for community-based clinical care and research whose aim is to reduce the incidence and prevalence of HIV/AIDS in the District of Columbia.

A plan was developed to create a research program to build a sustainable model for urban areas working to reduce the HIV/AIDS crisis. A needs assessment within the area’s medical community demonstrated a significant deficit in hepatitis C virus care and treatment. This led to the development of a Hepatitis branch within DC PFAP, rooted in direct subspecialty medical services and clinical research addressing the limitations of standard of care therapy.

The Hepatitis program is based at the Institute of Human Virology and operates out of three campuses: (1) clinical partners within Washington DC, (2) National Institutes of Health, Bethesda, MD and (3) University of Maryland Institute of Human Virology, Baltimore, MD. The overarching goals of the programs are to:

  • establish improved access to subspecialty care for underinsured patients with HIV
  • develop access to HIV and hepatitis related research for residents of DC
  • expand integrated care for hepatitis C in the community HIV clinics
  • provide national leadership in the development and delivery of effective, safe, convenient therapies, initially focusing on HCV

To date, over 1250 HIV and HCV infected patients have been linked to care and over 900 patients cured of hepatitis C through treatment with novel directly acting therapy within these subspecialty clinics. Through direct linkage to care, effective treatment, and continual outcome measurement, the Hepatitis program has developed an effective model for management of hepatitis C in an urban setting.


In 2016, DC PFAP produced a documentary, "The ASCEND Documentary: Patients, Providers, and Hepatitis C: An inside view of Hepatitis C treatment in an urban community health care setting."

DC PFAP Clinical Trials

The clinical trials listed below are by invitation only. Recruitment is only at DC PFAP sites.

Please note, The IHV has many clinical trials that are currently open and accepting participants. See Open Clinical Trials to learn more.

Click a trial name below to learn more about the trial.


Full Title: Geomapping Resistance and Viral Transmission in Risky Populations

Short Title: GRAVITY

Conducted by: Institute of Human Virology, University of Maryland

Principal Investigator: Sarah Kattakuzhy, MD

Sample Size: N= 1000

Accrual Ceiling: 1200

Study Population: Adults infected with HIV and/or HCV.

Accrual Period: 48 months

Study Design: This is an observational study for the collection of plasma samples and epidemiologic information. Participants will be seen for a single visit to provide samples for research at the time of HIV or HCV diagnosis.

Study Duration: Start Date: March 2016, End Date: March 2020

Primary Objective: Collection of plasma sample and epidemiologic information in individuals with diagnosis of HIV or HCV for phylogenetic analysis and phenotype/genotype associations.

Secondary Objectives: Identify prevalence of HCV resistance associated variants in patients with recent acquisition of HCV.

Exploratory Objectives: Phylogenetic and epidemiologic analysis of HIV and HCV to characterize viral transmission networks.


Full Title: A Novel model of Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior

Short Title: ANCHOR

Conducted by: Institute of Human Virology, University of Maryland

Principal Investigator: Elana Rosenthal, MD

Sample Size: N= 200

Accrual Ceiling: 400

Study Population: Adults infected with HCV

Accrual Period: 12 months

Study Design: This is an open label, non-randomized, observational pilot study to evaluate a model of care for treatment of hepatitis C in people with ongoing injection drug use. Participants will be treated with direct-acting antivirals (DAA) as per standard of care and will concomittantly be offered pre-exposure prophylaxis for HIV prevention and buprenorphine for treatment of opioid use disorder when clinically indicated.

Study Duration: Start Date: September 2016, End Date: March 2019

Primary Objective: To evauate the efficacy of DAAs for treatment of hepatitis C in people with ongoing injection drug use. 

Secondary Objectives:

  1. Evaluate uptake of PrEP
  2. Evaluate adherence to PrEP
  3. Evaluate uptake of buprenorphine when clinically indicated (objective restricted to HIPS)
  4. Evaluate retention in buprenorphine program (objective restricted to HIPS)

Exploratory Objectives:

  1. Rates of HCV reinfection after treatment with DAAs
  2. Rates of new HIV infection
  3. Immunologic and virologic correlates of protective immunity against reinfection

DC PFAP Subspecialty Clinics

Unity Health Care at Parkside and Walker Jones clinics
Washington, DC

Washington, DC

Varies weekly

In 2014, DC PFAP published a book titled "The Understanding of a Situation" which tells the stories of patients cured from hepatitis C through the DC PFAP program.